Pasar al contenido principal

DISFUNCION DEL RECEPTOR DE RIANODINA EN ENFERMEDADES PEDIATRICAS: CARACTERIZACION Y EVALUACION DE NUEVOS CANDIDATOS TERAPEUTICOS

PID2020-119780RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

  • Segarra Casas, Alba
  • Iruzubieta, Pablo
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Jericó, Ivonne
  • Fernández Torrón, Roberto
  • Maneiro, Miren
  • Marco Moreno, Pablo
  • Zelaya Huerta, M. Victoria
  • Rodríguez Santiago, Benjamín
  • Calafell i Majó, Francesc
  • Töpf, Ana
  • Straub, Volker
  • Vallejo Illarramendi, Ainara
  • López de Munain, Adolfo
  • Gallano, Pía
  • Gonzalez-Quereda, Lidia
Background and purpose: Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant. Methods: Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives. Results: Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype. Conclusion: Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia., This study was supported by Instituto de Salud Carlos III and FEDER, ‘Una manera de hacer Europa’, with the grants FIS PI18/01585 (LGQ and PG) and PI22/01859 (LGQ), MCIN/AEI/10.13039/501100011033 (PID20220-119780RB-I00, AVI) and Gobierno Vasco (GIU20/057 and 2,022,111,045, AVI). ASC was supported by the Ministerio de Universidades (Spain) with the grant FPU20/06692, and PMM was supported by a PhD fellowship from Fundacion Jesus De Gangoiti Barrera. MYO-SEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, CureLGMD2i, LGMD2D Foundation and Kurt+Peter Foundation, Muscular Dystrophy UK and Coalition to Cure Calpain 3 (VS). Analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute and the National Heart, Lung and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141 (VS). FC was supported by Agencia Estatal de Investigación ‘Unidad María de Maeztu’ (CEX2018-000792-M) and Agència de Gestió d'Ajuts Universitaris i de la Recerca (Generalitat de Catalunya, grant 2021SGR00466).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

  • Segarra-Casas, Alba
  • Iruzubieta, Pablo
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Jericó, Ivonne
  • Fernández-Torrón, Roberto
  • Maneiro, Miren
  • Marco-Moreno, Pablo
  • Zelaya-Huerta, M. Victoria
  • Rodríguez-Santiago, Benjamín
  • Calafell, Francesc
  • Töpf, Ana
  • Straub, Volker
  • Vallejo-Illarramendi, Ainara
  • López de Munain, Adolfo
  • Gallano, Pia
  • González-Quereda, Lidia
[Background and purpose] Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant., [Methods] Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives., [Results] Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype., [Conclusion] Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia., This study was supported by Instituto de Salud Carlos III and FEDER, ‘Una manera de hacer Europa’, with the grants FIS PI18/01585 (LGQ and PG) and PI22/01859 (LGQ), MCIN/AEI/10.13039/501100011033 (PID20220-119780RB-I00, AVI) and Gobierno Vasco (GIU20/057 and 2,022,111,045, AVI). ASC was supported by the Ministerio de Universidades (Spain) with the grant FPU20/06692, and PMM was supported by a PhD fellowship from Fundacion Jesus De Gangoiti Barrera. MYO-SEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, CureLGMD2i, LGMD2D Foundation and Kurt+Peter Foundation, Muscular Dystrophy UK and Coalition to Cure Calpain 3 (VS). Analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute and the National Heart, Lung and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141 (VS). FC was supported by Agencia Estatal de Investigación ‘Unidad María de Maeztu’ (CEX2018-000792-M) and Agència de Gestió d'Ajuts Universitaris i de la Recerca (Generalitat de Catalunya, grant 2021SGR00466)., With funding from the Spanish government through the "Maria de Maeztu Centre of Excellence" accreditation (CEX2018-000792-M), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

  • Segarra Casas, Alba
  • Iruzubieta, Pablo
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Jericó, Ivonne
  • Fernández Torrón, Roberto
  • Maneiro, Miren
  • Marco Moreno, Pablo
  • Zelaya Huerta, M. Victoria
  • Rodríguez Santiago, Benjamín
  • Calafell i Majó, Francesc
  • Töpf, Ana
  • Straub, Volker
  • Vallejo Illarramendi, Ainara
  • López de Munain, Adolfo
  • Gallano, Pía
  • Gonzalez-Quereda, Lidia
Background and purpose: Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant. Methods: Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives. Results: Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype. Conclusion: Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia., This study was supported by Instituto de Salud Carlos III and FEDER, ‘Una manera de hacer Europa’, with the grants FIS PI18/01585 (LGQ and PG) and PI22/01859 (LGQ), MCIN/AEI/10.13039/501100011033 (PID20220-119780RB-I00, AVI) and Gobierno Vasco (GIU20/057 and 2,022,111,045, AVI). ASC was supported by the Ministerio de Universidades (Spain) with the grant FPU20/06692, and PMM was supported by a PhD fellowship from Fundacion Jesus De Gangoiti Barrera. MYO-SEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, CureLGMD2i, LGMD2D Foundation and Kurt+Peter Foundation, Muscular Dystrophy UK and Coalition to Cure Calpain 3 (VS). Analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute and the National Heart, Lung and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141 (VS). FC was supported by Agencia Estatal de Investigación ‘Unidad María de Maeztu’ (CEX2018-000792-M) and Agència de Gestió d'Ajuts Universitaris i de la Recerca (Generalitat de Catalunya, grant 2021SGR00466).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

  • Moreno-Martínez, Laura
  • Gaja-Capdevila, Núria
  • Mosqueira-Martín, Laura
  • Herrando-Grabulosa, Mireia
  • Rodríguez-Gómez, Laura
  • González-Imaz, Klaudia
  • Calvo, Ana C.
  • Sagartzazu-Aizpurua, Maialen
  • Moreno-García, Leticia
  • Fuentes, José Manuel
  • Acevedo-Arozena, Abraham
  • Aizpurua, Jesús M.
  • Miranda, José Ignacio
  • López de Munain, Adolfo
  • Vallejo-Illarramendi, Ainara
  • Navarro, Xavier
  • Osta, Rosario
  • Gil Bea, Francisco Javier
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neu-rodegenerative disease with limited treatment options. ALS pathogenesis involvesintricate processes within motor neurons, characterized by dysregulated Ca 2+ influxand buffering in early ALS-affected motor neurones. This study proposes the modu-lation of ryanodine receptors (RyRs), key mediators of intracellular Ca 2+, as a thera-peutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activityas cytosolic calcium modulators through stabilizing RyR channel activity, weretested in the superoxide dismutase 1 (SOD1) G93A mouse model of ALS. Differentoutcomes were used to assess treatment efficacy, including electrophysiology, his-topathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP-010 was chosen for its centralnervous system availability and favourable in vitro pharmaco-toxicological profile.Chronic administration of MP-010 to SOD1 G93A mice produced preservation ofmotor nerve conduction, with the 61-mg kg 1 dose significantly delaying the onsetof motor impairment. This was accompanied by improved motor coordination,increased innervated endplates and significant preservation of motor neurones inthe spinal cord of treated mice. Notably, MP-010 treatment significantly extendedlifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP-010, exhibit prom-ising neuroprotective effects in ALS, highlighting their potential as novel therapeuticagents. Further investigations into the molecular mechanisms and clinical translat-ability of these compounds are needed for their application in ALS treatment., This work was funded by project CIBER-CALSPI2020/08-1, Grants CB06/05/1105 and CB06/05/0041 from the Instituto de Salud Carlos III of Spain, Grants PID2022-140354OB-I00 and PID2020-119780RB-100 from the Agencia Estatal de Investigación, co-funded by European Union (NextGenerationEU, Recovery, Transformation and Resilience Plan), and Grant IT1732-22 from the Basque Government - Eusko Jaurlaritza. F. J. G.-B. was funded byFundacion Roche Stop Fuga de Cerebros programme (BIO19/ROCHE/017/BD) and received support from the IKERBASQUE, Basque Foundation for Science (IKERBASQUE/PP/2022/003). L. M.-M. holds a PhD fellowship from the Euskal Herriko Univertsitatea (UPV/EHU) (PIF19/184). Open access funding provided by Universidad Pública de Navarra.